Science Department, Prostate Cancer Foundation, Santa Monica, California, USA.
Prostate. 2022 Oct;82(14):1346-1377. doi: 10.1002/pros.24409. Epub 2022 Jul 18.
The 28th Annual Prostate Cancer Foundation (PCF) Scientific Retreat was held virtually over 4 days, on October 28-29 and November 4-5, 2021.
The Annual PCF Scientific Retreat is a leading global scientific conference that focuses on first-in-field, unpublished, and high-impact basic, translational, and clinical prostate cancer research, as well as research from other fields with high probability for impacting prostate cancer research and patient care.
Primary areas of research discussed at the 2021 PCF Retreat included: (i) prostate cancer disparities; (ii) prostate cancer survivorship; (iii) next-generation precision medicine; (iv) PSMA theranostics; (v) prostate cancer lineage plasticity; (vi) tumor metabolism as a cancer driver and treatment target; (vii) prostate cancer genetics and polygenic risk scores; (viii) glucocorticoid receptor biology in castration-resistant prostate cancer (CRPC); (ix) therapeutic degraders; (x) new approaches for immunotherapy in prostate cancer; (xi) novel technologies to overcome the suppressive tumor microenvironment; and (xii) real-world evidence and synthetic/virtual control arms.
This article provides a summary of the presentations from the 2021 PCF Scientific Retreat. We hope that sharing this knowledge will help to improve the understanding of the current state of research and direct new advances in prostate cancer research and care.
第 28 届前列腺癌基金会（PCF）科学研讨会于 2021 年 10 月 28-29 日和 11 月 4-5 日以虚拟形式举办了 4 天。
年度 PCF 科学研讨会是一个领先的全球科学会议，专注于第一领域、未发表的和高影响力的基础、转化和临床前列腺癌研究，以及其他领域具有高概率影响前列腺癌研究和患者护理的研究。
2021 年 PCF Retreat 讨论的主要研究领域包括：（i）前列腺癌差异；（ii）前列腺癌生存；（iii）下一代精准医学；（iv）PSMA 治疗学；（v）前列腺癌谱系可塑性；（vi）肿瘤代谢作为癌症驱动因素和治疗靶点；（vii）前列腺癌遗传学和多基因风险评分；（viii）去势抵抗性前列腺癌（CRPC）中的糖皮质激素受体生物学；（ix）治疗性降解剂；（x）前列腺癌免疫治疗的新方法；（xi）克服抑制性肿瘤微环境的新技术；和（xii）真实世界证据和合成/虚拟对照臂。
本文总结了 2021 年 PCF 科学研讨会的演讲。我们希望分享这些知识将有助于提高对当前研究状况的理解，并指导前列腺癌研究和护理的新进展。
